This registry demonstrates excellent one-year clinical safety and efficacy of BioMatrix stents. The 1-year result shows that BioMatrix stent may be a suitable alternative as compared to contemporary DESs which are currently available in the market for simple as well complex disease.
Background:Overlapping first generation drug eluting stents (DES) have been demonstrated in preclinical models to show evidence of a persistent inflammatory response, fibrin deposition and delayed endothelialisation. The SIRTAX (Sirolimus-Eluting Versus Paclitaxel-Eluting Stents for Coronary Revascularization) Trial (nϭ1012) associated the implantation of overlapping first generation DES with impaired angiographic and adverse 3-year clinical outcomes, including death or myocardial infarction (MI). Methods: Patient level data from 5 controlled studies of the RESOLUTE Global Clinical Program evaluating the RESOLUTE zotarolimus-eluting stent (R-ZES) were pooled (nϭ5130). Enrolment criteria encompassed more complex patients, including acute MI, long lesions, unprotected left main, bifurcations, total occlusions, bypass grafts & visible thrombus. The position of the R-ZES in relation to the previous implanted stents during the index or staged procedures were reported by the study site as either 'separate,' 'abutting' or 'overlapping.' Comparisons of clinical outcomes -using propensity score adjustment of baseline anatomical and clinical characteristics -were undertaken between patients implanted with at least one overlapping DES against patients with no overlapping DES (Kaplan Meier analyses). Results: 644 of 5130 study patients (12.6%) underwent overlapping DES implantation. Baseline characteristics indicated that the implantation of overlapping DES compared to non-overlapping DES (nϭ4486) were performed more frequently in the RCA and in more complex coronary lesions. Thirty day, 1 & 2 year clinical outcomes indicated comparable all-cause death (2 year overlap vs. non overlap: 5.1% vs. 3.5%, pϭ0.13), cardiac death (3.0% vs. 2.1%, pϭ0.36), MACE (13.3% vs. 10.7%, pϭ0.19), target lesion (10.9% vs. 9.0%, pϭ0.41) & target vessel (12.8% vs. 10.6%, pϭ0.25) failure, and stent thrombosis (ARC definite/probable 1.4% vs. 0.9%, pϭ0.16). Conclusions: The adverse clinical outcomes associated with 1st generation DES were not apparent with 2nd generation DES. Overlapping second generation DES (compared to the non overlap) is safe & effective with comparable 2 year clinical outcomes, including repeat revascularisation.
Abstract:Transient bacteraemia following surgical procedures is a relatively common, but concomitant infective endocarditis in patient without any risk factor is a rare event. To the best of our knowledge, this is one of the few case reports of infective endocarditis following a urology procedure. We report a 57-year-old lady with pyelonephritis and renal calculus who developed vegetation's on chordae tendinae following renal surgery.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.